| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20043039 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS20017882 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS20022727 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS20037024 | HPV | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44009397 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44028155 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44030108 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44021446 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44027833 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
| TVIS44033068 | HTLV-1 | ENSG00000142192.22 | protein_coding | APP | No | No | 351 | A0A0A0MRG2 E9PG40 P05067 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | APP |
|---|---|
| DrugBank ID | DB01593 |
| Drug Name | Zinc |
| Target ID | BE0003392 |
| UniProt ID | P05067 |
| Regulation Type | cofactor |
| PubMed IDs | 24855651 |
| Citations | Mayer MC, Kaden D, Schauenburg L, Hancock MA, Voigt P, Roeser D, Barucker C, Than ME, Schaefer M, Multhaup G: Novel zinc-binding site in the E2 domain regulates amyloid precursor-like protein 1 (APLP1) oligomerization. J Biol Chem. 2014 Jul 4;289(27):19019-30. doi: 10.1074/jbc.M114.570382. Epub 2014 May 22. |
| Groups | Approved; Investigational |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Zn] |
| Pathways | Dihydropyrimidinase Deficiency; Rofecoxib Action Pathway; Losartan Action Pathway; AICA-Ribosiduria; Canavan Disease; Quinapril Action Pathway; Alkaptonuria; Eprosartan Action Pathway; gamma-Glutamyltransferase Deficiency; Pterine Biosynthesis; Sulindac Action Pathway; Rescinnamine Action Pathway; Piroxicam Action Pathway; Nabumetone Action Pathway; 2-Hydroxyglutric Aciduria (D and L Form); beta-Ureidopropionase Deficiency; Vitamin B6 Metabolism; Retinol Metabolism; Valsartan Action Pathway; Valdecoxib Action Pathway; Irbesartan Action Pathway; Adenosine Deaminase Deficiency; Hawkinsinuria; Methionine Metabolism; Ramipril Action Pathway; Benazepril Action Pathway; beta-Alanine Metabolism; Aspartate Metabolism; Diclofenac Action Pathway; Galactosemia |
| PharmGKB | PA451956 |
| ChEMBL | CHEMBL1201279 |
